Format

Send to

Choose Destination
Rheum Dis Clin North Am. 2001 May;27(2):389-403, ix-x.

Systemic low-dose glucocorticoid treatment in rheumatoid arthritis.

Author information

1
Rheumatology Unit, University Division of Medicine, Bristol Royal Infirmary, Bristol, United Kingdom. john.kirwan@bristol.ac.uk

Abstract

Glucocorticoids provide a large, immediate improvement in the symptoms of rheumatoid arthritis. At doses acceptable for long-term treatment, however, symptoms gradually re-emerge. Relatively low doses of glucocorticoids can, for several years, substantially retard the rate of joint destruction shown on radiographs. This differential effect implies the coexistence of two pathologic processes within diseased joints. Long term, low dose glucocorticoid therapy probably increases the risk of serious adverse effects, but an evidence-based case can be made for the limited use of low dose glucocorticoid treatment in early disease.

PMID:
11396099
DOI:
10.1016/s0889-857x(05)70208-8
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center